25892-08-4

Basic information

• Product Name: N1-(2,6-DIFLUORO-3-NITROPHENYL)ACETAMIDE
• Synonyms: N1-(2,6-DIFLUORO-3-NITROPHENYL)ACETAMIDE;N-(2,6-DIFLUORO-3-NITROPHENYL)ACETAMIDE;N-(2,6-Difluoro-3-nitrophenyl)acetaMid;N-(2,6-Difluoro-3-nitrophenyl)
• CAS NO: 25892-08-4
• Molecular Formula: C₈H₆F₂N₂O₃
• Molecular Weight: 216.14
• Product Categories: Phenyls & Phenyl-Het;Phenyls & Phenyl-Het
• Mol File: 25892-08-4.mol
• Article Data: 6

Chemical Properties

• Melting Point: 148 °C
• Boiling Point: 352.7 °C at 760 mmHg
• Flash Point: 167.1 °C
• Appearance: /
• Density: 1.513 g/cm³
• Vapor Pressure: 3.77E-05mmHg at 25°C
• Refractive Index: 1.573
• Storage Temp.: Sealed in dry,Room Temperature
• PKA: 12.03±0.70(Predicted)
• CAS DataBase Reference: N1-(2,6-DIFLUORO-3-NITROPHENYL)ACETAMIDE(CAS DataBase Reference)
• NIST Chemistry Reference: N1-(2,6-DIFLUORO-3-NITROPHENYL)ACETAMIDE(25892-08-4)
• EPA Substance Registry System: N1-(2,6-DIFLUORO-3-NITROPHENYL)ACETAMIDE(25892-08-4)

Safety Data

• Hazardous Substances Data: 25892-08-4(Hazardous Substances Data)

Usage

General Description

N1-(2,6-Difluoro-3-nitrophenyl)acetamide is a chemical compound with the molecular formula C8H7F2N3O3. It is a nitrophenylacetamide derivative that contains a nitro group and two fluorine atoms attached to a phenyl ring. N1-(2,6-Difluoro-3-nitrophenyl)acetamide is commonly used in organic synthesis and medicinal chemistry research as a building block for the synthesis of pharmaceuticals and other biologically active compounds. It may also have potential applications in the development of agrochemicals and materials science. Additionally, it is important to handle N1-(2,6-Difluoro-3-nitrophenyl)acetamide with caution as it may have hazardous properties and should only be used by trained professionals in a controlled laboratory setting.

InChI:InChI=1/C8H6F2N2O3/c1-4(13)11-8-5(9)2-3-6(7(8)10)12(14)15/h2-3H,1H3,(H,11,13)

Upstream product

• 5509-65-9 2,6-difluoroaniline 
• 3896-29-5 N-(2,6-difluorophenyl)acetamide 

Downstream Products

• 1437316-68-1 N-(3-((3-(9H-purin-6-yl)pyridin-2-yl)amino)-2,4-difluorophenyl)-4-fluorobenzenesulfonamide 
• 1380228-02-3 N-(3-((3-(9H-purin-6-yl)pyridin-2-yl)amino)-2,4-difluorophenyl)thiophene-2-sulfonamide 
• 1380228-04-5 N-(3-(3-(9H-purine-6-yl)pyridin-2-ylamino)-2,4-difluorophenyl) propane-1-sulfonamide 
• 1269421-10-4 N-(3-amino-2,4-difluorophenyl)-2-methylpropane-1-sulfonamide 
• 1380227-96-2 N-(3-(3-(9H-purin-6-yl)pyridin-2-ylamino)-2,4-difluorophenyl)propane-2-sulfonamide 
• 1392429-91-2 N-(3-amino-2,4-difluorophenyl)cyclopropanesulfonamide 
• 1380228-32-9 N-(3-(3-(9H-purin-6-yl)pyridin-2-ylamino)-2,4-difluorophenyl)cyclopropanesulfonamide 
• 1380228-16-9 N-(3-(3-(9H-purin-6-yl)pyridin-2-ylamino)-2,4-difluorophenyl)cyclohexanesulfonamide 
• 1380228-53-4 N-(3-(3-(9H-purin-6-yl)pyridin-2-ylamino)-2,4-difluorophenyl)benzenesulfonamide 

Relevant articles and documents

Purinylpyridinylamino-based DFG-in/αC-helix-out B-Raf inhibitors: Applying mutant versus wild-type B-Raf selectivity indices for compound profiling

One of the challenges for targeting B-RafV600E with small molecule inhibitors had been achieving adequate selectivity over the wild-type protein B-RafWT, as inhibition of the latter has been associated with hyperplasia in normal tissues. Recent studies suggest that B-Raf inhibitors inducing the 'DFG-in/αC-helix-out' conformation (Type IIB) likely will exhibit improved selectivity for B-RafV600E. To explore this hypothesis, we transformed Type IIA inhibitor (1) into a series of Type IIB inhibitors (sulfonamides and sulfamides 4-6) and examined the SAR. Three selectivity indices were introduced to facilitate the analyses: the B-RafV600E/B-RafWT biochemical (bS), cellular (cS) selectivity, and the phospho-ERK activation (pA). Our data indicates that α-branched sulfonamides and sulfamides show higher selectivities than the linear derivatives. We rationalized this finding based on analysis of structural information from the literature and provided evidence for a monomeric B-Raf-inhibitor complex previously hypothesized to be responsible for the desired B-RafV600E selectivity.

NEW TRIAZOLYLPHENYL SULFONAMIDES AS SERINE/THREONINE KINASE INHIBITORS

The present invention encompasses compounds of general formula (I) wherein the groups R2 to R4, A,X and m are defined as in claim 1, which are suitable for the treatment of diseases characterised by excessive or abnormal cell proliferation, pharmaceutical preparations which contain compounds of this kind and their use as medicaments.

Triazolylphenyl sulfonamides as serine/threonine kinase inhibitors

The present invention encompasses compounds of general formula (I) wherein the groups R2 to R4, A, X and m are defined as in claim 1, which are suitable for the treatment of diseases characterised by excessive or abnormal cell proliferation, pharmaceutical preparations which contain compounds of this kind and their use as medicaments.